Jason M. Broderick

“This study is important in that it represents a potential therapy option for patients in resource-limited parts of the world," said Glenn J. Hanna, MD.

“MajesTEC-9 is the second phase 3 study to show a significant PFS and OS benefit in the second-line setting and beyond with teclistamab-based therapy for RRMM,” said Roberto Mina, MD.

"The key finding is that more axillary surgery in itself does not improve survival in these patients," said Jana de Boniface, MD, PhD.

Notably, patients in EV-302 who converted from PR to CR achieved survival outcomes similar to those who achieved CR directly.

ROSELLA update shows consistent OS benefit with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, irrespective of prior taxane use.

The phase 3 POTOMAC study was the supporting trial for the FDA approval of the durvalumab combination for BCG-naive NMIBC.

Treatment with the ADC pivekimab sunirine can be initiated in an outpatient setting.

The approval of the TROP2-directed ADC datopotamab deruxtecan is supported by results from the phase 3 TROPION-Breast02 trial.

The results strengthen the evidence base for imetelstat's benefit in this high-risk, post-ruxolitinib myelofibrosis population.

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts shaping care.

Patients with high-risk myelodysplastic syndrome received the novel anti-IL1RAP antibody nadunolimab combined with azacitidine.

The sBLA for nogapendekin alfa inbakicept is supported by 36-month follow-up data from cohort B of the QUILT-3.032 trial.

Long-term real-world safety and effectiveness of darbepoetin alfa in MDS-related anemia are consistent with registration trial findings.

Investigators urge caution in interpreting these results, acknowledging the inherent limitations of unanchored, population-adjusted indirect trial comparisons.

The TRITON3 update supports rucaparib's role as an established option in the post-ARPI, pre-chemotherapy BRCA+ mCRPC setting.

"Sac-TMT may be able to address a critical unmet need for certain patients with advanced endometrial cancer," said Domenica Lorusso, MD, PhD.

The neoadjuvant and adjuvant FDA indications for T-DXd in HER2+ breast cancer are based on the DESTINY-Breast11 and DESTINY-Breast05 trials, respectively.

In ARASEC, darolutamide plus ADT significantly improved survival and disease control versus ADT alone in mHSPC, complementing ARANOTE outcomes.

The FDA approved atezolizumab for the adjuvant treatment of muscle invasive bladder cancer with ctDNA molecular residual disease after cystectomy.

UGN-103 (mitomycin) for intravesical solution sustained disease control through 6 months in the UTOPIA trial in recurrent intermediate-risk LG-NMIBC.

The FDA has granted suplexa, a non-engineered autologous cellular immunotherapy, fast track designation for patients with MSI-H colorectal cancer.

The phase 3 VOLGA trial showed perioperative durvalumab plus neoadjuvant enfortumab vedotin reduced the risk of death in muscle-invasive bladder cancer.

Mitomycin for intravesical solution demonstrated durable responses in 36-month follow-up data from the phase 3 ENVISION trial.

Sexual activity, sexual desire, and physical function were improved by testosterone replacement therapy in men with hypogonadism post-prostatectomy.

Emiltatug ledadotin is a B7-H4–directed antibody-drug conjugate that has shown antitumor activity in adenoid cystic carcinoma and other solid tumors.

The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan has elicited antitumor activity across subtypes of extrapulmonary neuroendocrine carcinomas.

INBRX-106 may act as a costimulatory agent and enhance pembrolizumab outcomes in head and neck squamous cell carcinoma.

The FDA has approvesd zenocutuzumab-zbco for previously treated NRG1 fusion–positive cholangiocarcinoma cholangiocarcinoma.

The FDA previously granted RZ-001 both orphan drug designation and fast track designation for hepatocellular carcinoma.

The phase 1/2 data led to the phase 3 RASolute 302 trial which supported the FDA's allowance of early access to daraxonrasib in PDAC.